Limits...
HMGB-1 as a novel predictor of disease severity and prognosis in patients with hemorrhagic fever with renal syndrome.

Du H, Li J, Yu H, Lian J, Zhang Y, Zhang Y, Bai X, Wang P - Mediators Inflamm. (2015)

Bottom Line: HMGB-1 was positively correlated with WBC and BUN and negatively correlated with PLT, ALB, and UA (P < 0.001).HMGB-1 showed statistical significance for predicting prognosis (AUC = 0.800, P < 0.001).The sensitivity and specificity of HMGB-1, WBC, PLT, and ALB used in combination for predicting outcome were better than those of single analyses (AUC = 0.892, P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Center of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.

ABSTRACT

Objective: To examine the predictive capacity of the high mobility group box protein-1 (HMGB-1) for disease severity and prognosis of hemorrhagic fever with renal syndrome (HFRS).

Methods: One hundred and five HFRS patients and 28 controls were studied. The concentrations of HMGB-1 in the blood were measured with a commercially available ELISA. The levels of white blood cells (WBC), platelets (PLT), hematocrit (HCT), albumin (ALB), blood urea nitrogen (BUN), serum creatinine (Scr), and uric acid (UA) were routinely tested in the same time frame.

Results: The levels of HMGB-1 increased with the severity of the disease (P < 0.001). HMGB-1 was positively correlated with WBC and BUN and negatively correlated with PLT, ALB, and UA (P < 0.001). HMGB-1 showed statistical significance for predicting prognosis (AUC = 0.800, P < 0.001). The sensitivity and specificity of HMGB-1, WBC, PLT, and ALB used in combination for predicting outcome were better than those of single analyses (AUC = 0.892, P < 0.001).

Conclusions: HMGB-1 can be considered a novel biomarker for severity and outcome in patients with HFRS. The use of HMGB-1, WBC, PLT, and ALB in combination to predict the outcome in patients with HFRS exhibited an acceptable level of diagnostic capability.

No MeSH data available.


Related in: MedlinePlus

Levels of HMGB-1 during the clinical course in patients with HFRS. The concentrations of HMGB-1 were presented as medians with IQR and were compared by the Nemenyi Rank test among the five groups ((a) and (b)). The concentrations of HMGB-1 were presented as medians with IQR and were compared by a Mann-Whitney U test for the acute stage and convalescent stage (c). ∗P < 0.05; ∗∗P < 0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4402477&req=5

fig1: Levels of HMGB-1 during the clinical course in patients with HFRS. The concentrations of HMGB-1 were presented as medians with IQR and were compared by the Nemenyi Rank test among the five groups ((a) and (b)). The concentrations of HMGB-1 were presented as medians with IQR and were compared by a Mann-Whitney U test for the acute stage and convalescent stage (c). ∗P < 0.05; ∗∗P < 0.001.

Mentions: The duration from disease onset to sample collection among the groups was not significantly different (P > 0.05) (Table 2). The levels of HMGB-1 in the patients from the acute stage were significantly higher than control (P < 0.001) and were increased with the severity of the disease. The levels of HMGB-1 in the patients in the convalescent stage were higher than the control group, except for the mild-type group (P < 0.05); the HMGB-1 levels of the critical-type group were higher compared with the mild- and moderate-type groups (P < 0.05) (Table 3, Figure 1).


HMGB-1 as a novel predictor of disease severity and prognosis in patients with hemorrhagic fever with renal syndrome.

Du H, Li J, Yu H, Lian J, Zhang Y, Zhang Y, Bai X, Wang P - Mediators Inflamm. (2015)

Levels of HMGB-1 during the clinical course in patients with HFRS. The concentrations of HMGB-1 were presented as medians with IQR and were compared by the Nemenyi Rank test among the five groups ((a) and (b)). The concentrations of HMGB-1 were presented as medians with IQR and were compared by a Mann-Whitney U test for the acute stage and convalescent stage (c). ∗P < 0.05; ∗∗P < 0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4402477&req=5

fig1: Levels of HMGB-1 during the clinical course in patients with HFRS. The concentrations of HMGB-1 were presented as medians with IQR and were compared by the Nemenyi Rank test among the five groups ((a) and (b)). The concentrations of HMGB-1 were presented as medians with IQR and were compared by a Mann-Whitney U test for the acute stage and convalescent stage (c). ∗P < 0.05; ∗∗P < 0.001.
Mentions: The duration from disease onset to sample collection among the groups was not significantly different (P > 0.05) (Table 2). The levels of HMGB-1 in the patients from the acute stage were significantly higher than control (P < 0.001) and were increased with the severity of the disease. The levels of HMGB-1 in the patients in the convalescent stage were higher than the control group, except for the mild-type group (P < 0.05); the HMGB-1 levels of the critical-type group were higher compared with the mild- and moderate-type groups (P < 0.05) (Table 3, Figure 1).

Bottom Line: HMGB-1 was positively correlated with WBC and BUN and negatively correlated with PLT, ALB, and UA (P < 0.001).HMGB-1 showed statistical significance for predicting prognosis (AUC = 0.800, P < 0.001).The sensitivity and specificity of HMGB-1, WBC, PLT, and ALB used in combination for predicting outcome were better than those of single analyses (AUC = 0.892, P < 0.001).

View Article: PubMed Central - PubMed

Affiliation: Center of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.

ABSTRACT

Objective: To examine the predictive capacity of the high mobility group box protein-1 (HMGB-1) for disease severity and prognosis of hemorrhagic fever with renal syndrome (HFRS).

Methods: One hundred and five HFRS patients and 28 controls were studied. The concentrations of HMGB-1 in the blood were measured with a commercially available ELISA. The levels of white blood cells (WBC), platelets (PLT), hematocrit (HCT), albumin (ALB), blood urea nitrogen (BUN), serum creatinine (Scr), and uric acid (UA) were routinely tested in the same time frame.

Results: The levels of HMGB-1 increased with the severity of the disease (P < 0.001). HMGB-1 was positively correlated with WBC and BUN and negatively correlated with PLT, ALB, and UA (P < 0.001). HMGB-1 showed statistical significance for predicting prognosis (AUC = 0.800, P < 0.001). The sensitivity and specificity of HMGB-1, WBC, PLT, and ALB used in combination for predicting outcome were better than those of single analyses (AUC = 0.892, P < 0.001).

Conclusions: HMGB-1 can be considered a novel biomarker for severity and outcome in patients with HFRS. The use of HMGB-1, WBC, PLT, and ALB in combination to predict the outcome in patients with HFRS exhibited an acceptable level of diagnostic capability.

No MeSH data available.


Related in: MedlinePlus